8-K: Neuronetics and Greenbrook TMS Announce Interim Order for Proposed Merger, Set Shareholder Meeting Dates

Neuronetics and Greenbrook TMS have received an interim court order for their proposed merger and have scheduled shareholder meetings for November 8, 2024, to vote on the transaction.

Summary

• Neuronetics and Greenbrook TMS have received an interim order from the Ontario Superior Court of Justice for their proposed merger.
• The merger will see Neuronetics acquire all outstanding shares of Greenbrook in an all-stock transaction.
• Greenbrook shareholders will receive 0.01149 shares of Neuronetics stock for each Greenbrook share, subject to adjustments.
• Post-merger, Neuronetics shareholders are expected to own approximately 57% and Greenbrook shareholders 43% of the combined company on a fully diluted basis.
• Both the Greenbrook and Neuronetics boards have unanimously recommended that their respective shareholders vote in favor of the merger.
• Special shareholder meetings for both companies are scheduled for November 8, 2024, to vote on the merger.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the progress of the merger and the unanimous support from both boards. However, it also acknowledges the risks and uncertainties associated with the transaction, which tempers the overall sentiment.

Positives

• The interim order from the court is a key step forward in the merger process.
• Unanimous board support from both companies indicates strong confidence in the merger.
• The merger is expected to create a larger, more diversified company in the mental health treatment space.
• The all-stock transaction allows Greenbrook shareholders to participate in the potential upside of the combined entity.

Negatives

• The merger is subject to shareholder approval, which introduces some uncertainty.
• The exchange ratio of 0.01149 shares of Neuronetics stock for each Greenbrook share is subject to adjustments, which could impact the final value received by Greenbrook shareholders.
• The merger could lead to integration challenges and potential disruptions to ongoing business operations.

Risks

• The merger is subject to various conditions, including shareholder approvals, which if not met could terminate the agreement.
• There are risks associated with integrating the two companies, including potential disruptions to operations and customer relationships.
• The combined company will face competition in the mental health treatment market.
• The success of the merger depends on the combined company's ability to achieve expected synergies and growth opportunities.
• The stock price of both companies could decline if the merger is not completed.

Future Outlook

The document outlines the next steps in the merger process, including shareholder meetings and the expected closing of the transaction, subject to approvals and conditions. The combined company anticipates leveraging the strengths of both entities to enhance their position in the mental health treatment market.

Management Comments

• The Greenbrook Board unanimously determined that the Arrangement is fair to Greenbrook Shareholders and in the best interests of Greenbrook.
• The Greenbrook Board unanimously recommends that the Greenbrook Shareholders vote in favour of the resolution relating to the Arrangement.
• The Neuronetics Board unanimously determined that the Arrangement is in the best interests of Neuronetics.
• The Neuronetics Board unanimously recommends that Neuronetics Stockholders vote in favor of the resolutions relating to the Arrangement.

Industry Context

This merger reflects a trend of consolidation in the mental health treatment industry, as companies seek to expand their reach and offerings. The combination of Neuronetics' NeuroStar TMS technology with Greenbrook's network of treatment centers could create a more comprehensive platform for addressing mental health needs.

Comparison to Industry Standards

• The all-stock merger is a common approach in the healthcare industry, allowing for the sharing of risk and potential upside between the merging entities.
• The exchange ratio of 0.01149 shares of Neuronetics stock for each Greenbrook share is within the range of typical merger transactions, but the final value will depend on the stock price of Neuronetics.
• The ownership split of 57% for Neuronetics shareholders and 43% for Greenbrook shareholders is a common outcome in mergers of this type, reflecting the relative size and value of the two companies.
• The use of a special committee of independent directors at Greenbrook to evaluate the merger is a standard practice to ensure fairness and protect shareholder interests.
• The requirement for shareholder approval from both companies is a typical condition in merger agreements, ensuring that shareholders have a say in the transaction.

Stakeholder Impact

• Shareholders of both companies will be impacted by the merger, with Greenbrook shareholders receiving Neuronetics stock.
• Employees of both companies may experience changes as the two organizations integrate.
• Customers of both companies may see changes in service offerings and delivery.
• The merger could impact suppliers and other business partners of both companies.

Next Steps

• Greenbrook and Neuronetics will hold special shareholder meetings on November 8, 2024, to vote on the merger.
• The companies will continue to work towards satisfying the remaining conditions for the merger.
• The combined company will begin integration planning upon successful completion of the merger.

Key Dates

Keywords

merger, acquisition, Neuronetics, Greenbrook TMS, shareholder meeting, interim order, all-stock transaction, TMS, mental health, NeuroStar, Spravato